Audentes Therapeutics Obtains $75,000,000 New Funding Round

  • Feed Type
  • Date
    7/20/2016
  • Company Name
    Audentes Therapeutics
  • Mailing Address
    101 Montgomery Street. San Francisco, CA 94104 USA
  • Company Description
    Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.
  • Website
    http://www.audentestx.com
  • Transaction Type
    IPO
  • Transaction Amount
    $75,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    We currently intend to use the net proceeds from this offering for the following purposes: approximately $18.0 to $20.0 million to advance AT132 for the treatment of XLMTM through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $13.0 to $15.0 million to advance AT342 for the treatment of Crigler-Najjar through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT982 for the treatment of Pompe disease through preliminary results from a Phase 1/2 clinical trial expected in the second half of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT307 for the treatment of CASQ2-CPVT through submission of an IND or CTA in 2017; approximately $7.0 to $10.0 million to operate and expand our internal manufacturing facility; and the remainder for working capital and other general corporate purposes,
  • M&A Terms

Trending on Xconomy